Loading...

Member Profile

Home / Members

Advagene Biopharma Co., Ltd.




Chairman
  • Yu Shen Hsu
Date Established
  • 2006/09/19
TWSE Stock ID
  • 6709
Phone Number
  • +886-2-2797-0073
Address
  • 6F., No.308, Sec.1, Neihu Rd., Neihu Dist., Taipei City 114, Taiwan (R.O.C.)
Website Theraputic Fields
  • Immunology
  • Infections and Infectious Diseases
  • Pulmonary/Respiratory Diseases
Product Classification
  • Biologics
  • Vaccines
  • Technology Platform

Advagene Biopharma Co., Ltd. is a biopharmaceutical company that aims to develop mucosal immunotherapy, committed to providing human beings around the world the biopharmaceutical development for better epidemic prevention and treatment.
Advagene’s core technology: detoxified LT adjuvant (LTh (αK)) platform, can regulate not only humoral but also mucosal immunity and enhance the production of mucosal immunoglobulin A (IgA), which can fortify the efficacy of vaccines and can change the transmission route; such development has high medical potential. Advagene has applied this into the development of nasal influenza vaccine (AD07030), respiratory allergy treatment (AD17002-AI), COVID-19 immunotherapy (AD17002-SC), nasal COVID-19 vaccine, and other vaccines, among which nasal flu vaccine (AD07030) phase II clinical trial has been completed at the end of the first season in 2019. allergy treatment (AD17002-AI) phase I/II clinical trial is completed and administered in 2020, and COVID-19 immunotherapy (AD17002-SC) phase II is initiated in 2021 (Taiwan) and phase II/III in Indonesia.

Product Pipelines

Please move your mouse cursor over abbreviations with periods to see their full names.

Company Milestones

   2014 Founded and received technology transfer from DCB on detoxified LT platforms.
   2018 Listed company on TPEx emerging stock board.
   2019 Completed phase II clinical trial of nasal spray influenza vaccine.
   2020 Nasal spray new drug AD17002-AI applied to allergic rhinitis treatment in phase Ib/IIa human trial has been completed.
   2020 Application of new drug AD17002-SC to COVID-19 immunotherapy was selected as a capstone project by CDE.
   2020 Obtained the technology authorization from National Institutes of Health(NIH), to use influenza virus particle platform to develop SARS-Cov-2 antigen. This antigen technology will be used for the development of the second-generation nasal spray COVID-19 vaccine, which can induce both serum and mucosal antibodies after vaccination. And it provides injection-free vaccination and additional mucosal protection.
   2021 New drug AD17002-SC for the treatment of COVID-19 was approved by TFDA to perform phase II human clinical trials.
   2022 AD17002-SC for the treatment of COVID-19 was approved by BPOM to perform phase II/III human clinical trials in Indonesia.